热门资讯> 正文
Calliditas的Kinpegyo获得欧盟批准，司塔纳西布研究达到终点
2024-07-27 03:52
- Calliditas (NASDAQ:CALT) said its partner STADA has received full EU marketing authorization for the drug Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy, or IgAN.
- Kinpeygo is marketed in the EU and UK by the company's commercial partner STADA Arzneimittel. Calliditas (CALT) said the approval will trigger a milestone payment of EUR 10M, which it plans to recognize in Q3.
- Calliditas (CALT) also reported that a Phase 2b study for its drug setanaxib in patients with primary biliary cholangitis and elevated liver stiffness met its primary endpoint.
- The company expects topline data from a Phase 2 study of setanaxib in idiopathic pulmonary fibrosis in Q4 2024/Q1 2025 and from a Phase 2 proof-of-concept study in Alport syndrome in 2025.
More on Calliditas Therapeutics
- Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
- Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript
- Calliditas Therapeutics AB (publ) 2024 Q1 - Results - Earnings Call Presentation
- Citi downgrades Calliditas to neutral, cites takeover offer
- Asahi Kasei offers to buy Calliditas Therapeutics for $1.1B
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
